This is a StreetInsider.com Premium Only Page

(KNSA) – StreetInsider.com Reports

Apr 23, 2024 08:37 AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 11c; raises guidance

Apr 3, 2024 04:10 AM Kiniksa (KNSA) PT Raised to $30 at Wedbush

Apr 2, 2024 07:31 AM Kiniksa Pharmaceuticals (KNSA) Announces Development Indication for Abiprubart

Feb 28, 2024 07:35 AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q4 EPS by 46c, provides product guidance

Jan 19, 2024 08:15 AM Kiniksa (KNSA) PT Raised to $24 at JPMorgan

Jan 4, 2024 07:34 AM Kiniksa Pharmaceuticals (KNSA) Provides Corporate Update

Jan 2, 2024 06:09 AM Kiniksa (KNSA) PT Raised to $25 at Wedbush

Nov 22, 2023 07:30 AM Kiniksa (KNSA) PT Lowered to $23 at JPMorgan

Oct 31, 2023 08:03 AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q3 EPS by 3c

Jul 25, 2023 02:54 PM Kiniksa (KNSA) PT Raised to $32 at Goldman Sachs

Jul 25, 2023 12:17 PM Kiniksa (KNSA) PT Raised to $23 at Wedbush

Jul 25, 2023 07:32 AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 35c

May 2, 2023 07:35 AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Misses Q1 EPS by 2c; offers guidance

Mar 13, 2023 03:38 AM Kiniksa (KNSA) PT Raised to $18 at Evercore ISI

Mar 9, 2023 06:54 AM Kiniksa (KNSA) PT Raised to $20 at JPMorgan

Feb 28, 2023 04:02 PM Kiniksa (KNSA) PT Lowered to $20 at Wedbush

Aug 3, 2022 07:34 AM Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 14c

Aug 3, 2022 07:29 AM Kiniksa Pharmaceuticals (KNSA) Announces Global License Agreement with Genentech for Vixarelimab

Aug 3, 2022 07:24 AM Kiniksa Pharmaceuticals Ltd. (KNSA) Halted, News Pending

May 6, 2022 04:18 PM Kiniksa Pharmaceuticals Ltd. (KNSA) Announces 28.68M Share Offering by Selling Stockholders

May 6, 2022 04:11 PM Kiniksa Pharmaceuticals Ltd. (KNSA) Files $400M Mixed Shelf Registration Statement

May 3, 2022 03:16 PM Kiniksa (KNSA) PT Lowered to $16 at Evercore ISI

Mar 16, 2022 06:47 AM JPMorgan's Top 99 Names to Buy/Own On The Market Pullback

Feb 23, 2022 09:10 AM Kiniksa (KNSA) PT Lowered to $28 at BofA Securities

Feb 22, 2022 05:39 PM Kiniksa (KNSA) PT Lowered to $24 at Goldman Sachs

Feb 22, 2022 07:59 AM Kiniksa Pharmaceuticals (KNSA) and Huadong Medicine Enter Strategic Collaboration

Feb 16, 2022 07:23 AM Kiniksa (KNSA) PT Lowered to $28 at Goldman Sachs

Dec 29, 2021 04:58 AM Kiniksa (KNSA) PT Lowered to $34 at BofA Securities

Dec 28, 2021 04:57 PM UPDATE: Kiniksa (KNSA) PT Lowered to $20 at Evercore ISI

Dec 28, 2021 09:30 AM Pre-Open Stock Movers 12/28: (FTK) (KNDI) (APPS) Higher; (BXRX) (KNSA) (INNV) Lower (more...)

Dec 28, 2021 07:05 AM Kiniksa Pharmaceuticals Ltd. (KNSA) Sinks 19% as Trial of COVID-Related ARDS Treatment Fails

Dec 28, 2021 06:59 AM Kiniksa Pharmaceuticals Ltd. (KNSA) Announces Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS Did Not Meet Endpoints

Nov 2, 2021 05:13 AM Kiniksa (KNSA) PT Lowered to $27 at JPMorgan

Aug 24, 2021 11:25 AM Kiniksa (KNSA) PT Lowered to $30 at JPMorgan

Jun 9, 2021 09:27 AM Pre-Open Stock Movers 06/09: (AEMD) (WISH) (SLDB) Higher; (ODNS) (CPB) (CMTL) Lower (more...)

Jun 8, 2021 05:54 PM After-Hours Stock Movers 06/08: (LYRA) (FSR) (LMNR) Higher; (ONDS) (CMTL) (PATH) Lower (more...)

Jun 8, 2021 04:01 PM Kiniksa Pharmaceuticals Ltd. (KNSA) Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis

Jun 8, 2021 07:34 AM Kiniksa (KNSA) Outlines Next Steps for the Development of Mavrilimumab

May 5, 2021 06:21 AM Kiniksa Pharmaceuticals Ltd. (KNSA) Reports Positive Final Data from Phase 1 Trial of KPL-404

Apr 1, 2021 08:05 AM Kiniksa Pharmaceuticals (KNSA) Announces Commercial Availability of ARCALYST for Recurrent Pericarditis

Mar 19, 2021 09:29 AM Pre-Open Stock Movers 03/19: (MRKR) (ZKIN) (CLVS) Higher; (IDRA) (SKLZ) (ROAD) Lower (more...)

Mar 19, 2021 08:59 AM Kiniksa (KNSA) PT Raised to $37 at BofA Securities After the FDA Approved Rilonacept

Mar 18, 2021 05:47 PM After-Hours Stock Movers 03/18: (MRKR) (TKAT) (KNSA) Higher; (ROAD) (NKE) (HIMS) Lower (more...)

Mar 18, 2021 04:33 PM Kiniksa (KNSA) Announces FDA Approval of ARCALYST for Recurrent Pericarditis

Dec 22, 2020 08:01 AM Kiniksa Pharmaceuticals Ltd. (KNSA) Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation

Dec 15, 2020 08:01 AM Kiniksa Pharmaceuticals Ltd. (KNSA) Begins Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis

Nov 30, 2020 08:04 AM Kiniksa Pharmaceuticals (KNSA) Announces Preliminary Data from Phase 1 Trial of KPL-404

Nov 23, 2020 08:08 AM Kiniksa Pharmaceuticals (KNSA) Announces U.S. FDA Acceptance of sBLA and Priority Review for Rilonacept in Recurrent Pericarditis

Nov 17, 2020 08:06 AM Kiniksa Pharmaceuticals Ltd. (KNSA) Reports Publication of Rilonacept Phase 3 Data in Recurrent Pericarditis

Nov 16, 2020 08:06 AM Kiniksa Pharmaceuticals (KNSA) Announces Breakthrough Therapy Designation Granted to Vixarelimab for the Treatment of Pruritus Associated with Prurigo Nodularis